| Expression pattern: |
UP |
| Associated gene: |
IGF2BP1, IGF2BP2, AIF, MIB1, METTL3, ALKBH5, FTO |
| Associated microRNA: |
- |
| Biological function: |
promotes HCC cell growth and prevents cisplatin-induced apoptosis, contributing to chemoresistance |
| Molecular mechanism: |
m6A modification enables IGF2BP1-mediated translation of circMAP3K4 into circMAP3K4-455aa; the peptide binds AIF to inhibit AIF cleavage and nuclear translocation; circMAP3K4-455aa is ubiquitinated by MIB1 and degraded via the proteasome |
| Biological pathway or process: |
apoptosis (inhibits); chemoresistance (promotes); proliferation (promotes); ubiquitination (other); m6A modification (promotes) |
| Detected method: |
Q
B
H
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Northern Blot; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; ROC Analysis; Survival Analysis; Cohort Study; Bioinformatics Analysis; Transfection; CCK8; Annexin V/PI Flow Cytometry; TUNEL; Western Blot; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; MeRIP / MeRIP-seq; RNA-seq; In Vivo Animal Model; H&E Staining; IF (Immunofluorescence); Co-IP |
| Clinical significance: |
High circMAP3K4 level is an independent prognostic factor for adverse overall survival and adverse disease-free survival in HCC patients |
| Description: |
circMAP3K4 is upregulated in HCC and serves as an adverse prognostic factor. Via m6A modification, IGF2BP1 promotes translation of circMAP3K4 into the peptide circMAP3K4-455aa, which binds AIF to reduce AIF cleavage and nuclear translocation, thereby suppressing cisplatin-induced apoptosis and contributing to chemoresistance; the peptide is ubiquitinated by MIB1 for proteasomal degradation. |
| Confidence score: |
0.904 |